Ad-RTS-hIL-12

AXP000146.1 · Viral vector gene therapy

Platform
adenovirus (Ad5, RheoSwitch-regulated)
Targets
IL12A; IL12B
Originator
Ziopharm Oncology
Sponsor
Alaunos Therapeutics

Names

NameTypeSource
Ad-RTS-hIL-12preferred name, codecurator, ncit
INXN-2001codencit
Ad-RTS-hIL-12 + veledimex ambiguoussynonymncit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
non-replicating adenoviral vector; human IL-12 p70 under RheoSwitch Therapeutic System control, induced by oral veledimex
Transgenes
IL12A, IL12B
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C143953

Approvals

No regulatory approval recorded.

Clinical trials (8)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04006119Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaTerminatedPhase 22019-08-012021-08-0540Glioblastoma
NCT03679754Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102CompletedPhase 12018-09-052019-04-0236Glioblastoma
NCT03636477A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102CompletedPhase 12018-06-182020-10-1521Glioblastoma
NCT03330197A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPGTerminatedPhase 1/22017-09-262021-09-106Diffuse Intrinsic Pontine Glioma; Pediatric Brain Tumor
NCT02423902A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast CancerTerminatedPhase 1/22015-07-182016-07-199Metastatic Breast Cancer
NCT02026271A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant GliomaCompletedPhase 12015-062019-0840Anaplastic Oligoastrocytoma; Glioblastoma Multiforme
NCT01703754Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.TerminatedPhase 22013-04-042014-08-0712Breast Cancer Nos Metastatic Recurrent
NCT01397708Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat MelanomaCompletedPhase 1/22011-082014-0926Melanoma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 34850166Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.Neuro-oncology2022cited by trial NCT03636477
PMID 31413142Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.Science translational medicine2019cited by trial NCT02026271

Notes

Intratumoral adenovirus carrying human IL-12 under the RheoSwitch Therapeutic System, switched on by the oral activator ligand veledimex (a separate agent). Phase 1/2 in recurrent glioblastoma and in breast cancer; INXN-2001 is the Intrexon code. The related product INXN-3001 (NCIt C101789) is autologous dendritic cells transduced with the same switch and is a different program, not entered here.

How to cite

Ad-RTS-hIL-12 (AXP000146.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000146.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.